Australia markets close in 1 hour 8 minutes

Gamida Cell Ltd. (GMDA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
3.3900+0.7500 (+28.41%)
At close: 04:00PM EDT
3.4900 +0.10 (+2.95%)
After hours: 07:57PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.6400
Open2.7200
Bid0.0000 x 3000
Ask0.0000 x 1800
Day's range2.7000 - 3.6588
52-week range1.4800 - 5.8400
Volume5,679,974
Avg. volume475,927
Market cap203.348M
Beta (5Y monthly)1.71
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

    BOSTON, August 10, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces dosing of the first patient in a company-sponsored Phase 1/2 study evaluating a cryopreserved, readily available formulation of GDA-201 for the treatment of follicular and diffuse large B cell lymphomas (NCT05296525).

  • Business Wire

    Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

    BOSTON, August 08, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company.

  • Business Wire

    Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

    BOSTON, August 01, 2022--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s Biologics License Application (BLA) for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. Omidubicel is a first-in-class, ad